Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer mortality in the United States and the second leading cause of cancer mortality worldwide. Sorafenib is the only food and drug administration (FDA) approved as first line systemic treatment in HCC. Regorafenib and nivolumab are the...

Descripción completa

Detalles Bibliográficos
Autores principales: Contratto, Merly, Wu, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952267/
https://www.ncbi.nlm.nih.gov/pubmed/29770170
http://dx.doi.org/10.4251/wjgo.v10.i5.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952267/
https://www.ncbi.nlm.nih.gov/pubmed/29770170
http://dx.doi.org/10.4251/wjgo.v10.i5.108

Ejemplares similares